Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases  

作　　者：Jingjing Ren Xiao-Qi Wang Tetsushi Nakao Peter Libby Guo-Ping Shi 

机构地区：[1]Department of Medicine,Brigham and Women's Hospital and Harvard Medical School,Boston,Massachusetts 02115,USA

出　　处：《Cardiology Discovery》2023年第3期166-182,共17页心血管病探索（英文）

基　　金：supported by the National Heart,Lung,and Blood Institute (HL151627 and HL157073 to Guo-Ping Shi,HL134892 and HL163099 to Peter Libby);the National Institute of Neurological Disorders and Stroke (AG063839 to Guo-Ping Shi).

摘　　要：Severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2)infection can lead to a cytokine storm,unleashed in part by pyroptosis of virus-infected macrophages and monocytes.Interleukin-6(IL-6)has emerged as a key participant in this ominous complication of coronavirus disease 2019(COVID-19).IL-6 antagonists have improved outcomes in patients with COVID-19 in some,but not all,studies.IL-6 signaling involves at least 3 distinct pathways,including classic-signaling,trans-signaling,and trans-presentation depending on the localization of IL-6 receptor and its binding partner glycoprotein gp130.IL-6 has become a therapeutic target in COVID-19,cardiovascular diseases,and other inflammatory conditions.However,the efficacy of inhibition of IL-6 signaling in metabolic diseases,such as obesity and diabetes,may depend in part on cell type-dependent actions of IL-6 in controlling lipid metabolism,glucose uptake,and insulin sensitivity owing to complexities that remain to be elucidated.The present review sought to summarize and discuss the current understanding of how and whether targeting IL-6 signaling ameliorates outcomes following SARS-CoV-2 infection and associated clinical complications,focusing predominantly on metabolic and cardiovascular diseases.

关 键 词：INTERLEUKIN-6 SARS-CoV-2 COVID-19 Metabolic disease Cardiovascular disease TOCILIZUMAB Olamkicept 

分 类 号：R56[医药卫生—呼吸系统] R54[医药卫生—内科学]